Trastuzumab

54 trials 30 recruiting LOncology

Filter these 54 trials by condition, phase, country and more.

Open in Search →

54 Registered trials

30 Recruiting

20 Completed trials

35 Sponsors

21 Countries

Phase III

Phase II

Phase III: 19 Phase II/III: 4 Phase II: 23 Phase I/II: 4 Phase IV: 3 Phase I (Other): 1

Oversight events:

2 serious breaches 5 temporary halts 2 unexpected events across 6 trials

View oversight register →

Indications tested

HER2 positive breast cancer 11 Breast cancer 4 Breast cancer stage III 3 Breast cancer stage II 3 Breast cancer metastatic 3 HER2 positive gastric cancer 2 Metastatic gastric cancer 2 Colorectal cancer metastatic 1 Gastrooesophageal cancer 1 Invasive breast carcinoma 1 Triple negative breast cancer 1 Cholangiocarcinoma 1

Sponsors using this IMP

Unicancer 5 AstraZeneca AB 4 F. Hoffmann-La Roche AG 4 Jazz Pharmaceuticals Ireland Limited 3 Karolinska University Hospital 3 Alx Oncology Inc. 2 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 2 Institut Curie 2 Institut Jules Bordet 2 Rigshospitalet 2 Seagen Inc. 2 Alliance Foundation Trials LLC 1

All trials — page 3

54 total

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Admi… Ended

2023-506380-33-00 Phase III 3 countries F. Hoffmann-La Roche AG
Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) Ended

2024-512826-26-00 Phase II 1 country Institut Gustave Roussy
Tucatinib and trastuzumab in solid tumors with HER2 alterations Ended

2024-511481-37-00 Phase II 3 countries Seagen Inc.
Study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patie… Ended

2024-512050-13-00 Phase III 1 country Novartis Pharma AG
Inhibition of AKT in combination with antibodies targeting the protein HER2 in patients with advanced or metastatic breast cancer and with a… Ended

2023-508826-92-00 Phase I (Other) 1 country Solti Group
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended

2023-508253-98-00 Phase III 6 countries Merck Sharp & Dohme LLC

Showing 49–54 of 54 trials

← All drugs A–Z